SCHEMBL21484844

SCHEMBL21484844

N#CCC(=O)Nc1nc(-c2cccs2)cs1

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 10/20 0.66
KMT2A Q03164 10/20 0.66
LMNA P02545 7/20 0.66
TP53 P04637 3/20 0.66
NPC1 O15118 5/20 0.64
MAPK1 P28482 4/20 0.64
KDM4E B2RXH2 3/20 0.64
HSD17B10 Q99714 1/20 0.64
MAPT P10636 12/20 0.62
TSHR P16473 4/20 0.62
RAB9A P51151 5/20 0.61
HTT P42858 3/20 0.61
GAA P10253 2/20 0.61
ABL1 P00519 1/20 0.59
NPSR1 Q6W5P4 3/20 0.57
F2 P00734 2/20 0.56
SMN1; SMN2 Q16637 5/20 0.55
ALDH1A1 P00352 4/20 0.55
HPGD P15428 1/20 0.54
ALOX15 P16050 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21484876 0.82 ABL1 (0.59) MEN1KMT2ALMNATP53NPC1
SCHEMBL21484713 0.82 ABL1 (0.68) MEN1KMT2ALMNANPC1MAPK1
SCHEMBL21484835 0.82 ABL1 (0.68) MEN1KMT2ANPC1KDM4EMAPT
SCHEMBL21484883 0.81 LMNA (0.64) MEN1KMT2ALMNATP53NPC1
SCHEMBL21484823 0.81 ABL1 (0.58) MEN1KMT2ALMNATP53NPC1
SCHEMBL29047581 0.81 KDM4E (0.70) MEN1KMT2ALMNANPC1KDM4E
SCHEMBL21484850 0.80 ABL1 (0.69) MEN1KMT2ALMNANPC1MAPK1
SCHEMBL21484633 0.80 ABL1 (0.65) MEN1KMT2ALMNANPC1MAPK1
SCHEMBL21484682 0.79 ALDH1A1 (0.64) MEN1KMT2ALMNANPC1KDM4E
SCHEMBL13842694 0.78 NPC1 (1.00) MEN1KMT2ALMNATP53NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11584742-B2 Substituted aminothiazoles as inhibitors of nucleases MASARYKOVA UNIVERZITA (CZ) 2023-02-21 US disclosed
US-11584742-B2 Substituted aminothiazoles as inhibitors of nucleases MASARYKOVA UNIVERZITA (CZ) 2023-02-21 US disclosed
US-20220002282-A1 SUBSTITUTED AMINOTHIAZOLES AS INHIBITORS OF NUCLEASES MASARYKOVA UNIVERZITA (CZ) 2022-01-06 US disclosed
US-20220002282-A1 SUBSTITUTED AMINOTHIAZOLES AS INHIBITORS OF NUCLEASES MASARYKOVA UNIVERZITA (CZ) 2022-01-06 US disclosed
EP-3556755-B1 SUBSTITUTED AMINOTHIAZOLES AS INHIBITORS OF NUCLEASES UNIV MASARYKOVA (CZ) 2021-11-17 EP disclosed
EP-3556755-B1 SUBSTITUTED AMINOTHIAZOLES AS INHIBITORS OF NUCLEASES UNIV MASARYKOVA (CZ) 2021-11-17 EP disclosed
CN-112313229-A Substituted aminothiazoles as inhibitors of nucleases 马萨里克大学 2021-02-02 CN disclosed
WO-2019201865-A1 SUBSTITUTED AMINOTHIAZOLES AS INHIBITORS OF NUCLEASES MASARYKOVA UNIVERZITA (CZ) 2019-10-24 WO disclosed
WO-2019201865-A1 SUBSTITUTED AMINOTHIAZOLES AS INHIBITORS OF NUCLEASES MASARYKOVA UNIVERZITA (CZ) 2019-10-24 WO disclosed
EP-3556755-A1 SUBSTITUTED AMINOTHIAZOLES AS INHIBITORS OF NUCLEASES Masarykova univerzita (CZ) 2019-10-23 EP disclosed
EP-3556755-A1 SUBSTITUTED AMINOTHIAZOLES AS INHIBITORS OF NUCLEASES Masarykova univerzita (CZ) 2019-10-23 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11584742-B2 Substituted aminothiazoles as inhibitors of nucleases RNASEH1, DNASE1, FEN1 MEN1 1727/4885KMT2A 805/4885LMNA 522/4885
US-20220002282-A1 SUBSTITUTED AMINOTHIAZOLES AS INHIBITORS OF NUCLEASES RNASEH1, DNASE1, FEN1 MEN1 1727/4885KMT2A 805/4885LMNA 522/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.